Clinical Trials | NORM: Nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have Nodular lymphocyte-predominant Hodgkin lymphoma. The purpose of this study is to compare the usual treatment rituximab alone to using mosunetuzumab alone. Treatment with mosunetuzumab instead of the usual treatment rituximab could shrink your cancer with a long-lasting response. This study has two study groups. You will be told which group you are in. A computer will be used to assign you to one of the study groups. This process is called “randomization.” It means that your doctor will not choose and you cannot choose which study group you are in. You will be put into a group by chance. You will have an equal chance of being in Group 1 or Group 2. • Group 1: If you are in this group, you will get the study drug mosunetuzumab. You will get this drug through an injection under your skin at an increasing dose on the days 1, 8, and 15 of the first cycle, followed by a fixed dose on day 1 of all subsequent cycles. Each cycle lasts 21 days, and you will receive a total of eight cycles. There will be about 28 people in this group. • Group 2: If you are in this group, you will get the usual drug used to treat this type of cancer, rituximab, either through a vein in the arm or an injection under your skin. You will get this drug through a vein in the arm on days 1, 8, 15, and 22 of each cycle. Each cycle lasts 28 days, and you will receive two cycles which will be eight weeks apart. There will be about 28 people in this group. You will receive study treatment for up to 5 months. Your doctor will then follow up with you for 5 years after study treatment. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://www.clinicaltrials.gov/study/NCT05886036 [email protected]